Technical Analysis for LQDA - Liquidia Technologies, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 2.77 | -4.15% | -0.12 |
Earnings due: May 10
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Up |
Historical LQDA trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 50 DMA | Bearish | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
MACD Bullish Centerline Cross | Bullish | 0.00% | |
Upper Bollinger Band Walk | Strength | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
Crossed Above 50 DMA | Bullish | -4.15% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -4.15% | |
Upper Bollinger Band Touch | Strength | -4.15% | |
50 DMA Resistance | Bearish | -2.12% | |
Pocket Pivot | Bullish Swing Setup | -2.12% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Non-ADX 1,2,3,4 Pullback Entry | about 4 hours ago |
Rose Above Previous Day's High | about 4 hours ago |
Rose Above Upper Bollinger Band | about 4 hours ago |
Down 3% | about 4 hours ago |
Down 2 % | about 4 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/10/2021
Liquidia Technologies, Inc. Description
Liquidia Technologies, Inc. (“Liquidia”) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients. PRINT® is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia’s lead product candidate, LIQ861, currently being evaluated in a Phase 3 clinical trial (INSPIRE), is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, disposable dry powder inhaler. LIQ865, for which Liquidia has recently completed a U.S. Phase 1b clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to develop their own product candidates across a wide range of therapeutic areas, molecule types and routes of administration, leveraging Liquidia’s PRINT® technology.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Pharmaceutical Pharmaceutical Industry Pain Medication Hypertension Clinical Trial Opioid Uniform Pulmonary Arterial Hypertension Bupivacaine Inhaler Treprostinil
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 12.1 |
52 Week Low | 2.34 |
Average Volume | 1,105,035 |
200-Day Moving Average | 3.97 |
50-Day Moving Average | 2.85 |
20-Day Moving Average | 2.66 |
10-Day Moving Average | 2.70 |
Average True Range | 0.20 |
ADX | 15.5 |
+DI | 24.85 |
-DI | 14.43 |
Chandelier Exit (Long, 3 ATRs ) | 2.42 |
Chandelier Exit (Short, 3 ATRs ) | 2.95 |
Upper Bollinger Band | 2.91 |
Lower Bollinger Band | 2.40 |
Percent B (%b) | 0.73 |
BandWidth | 19.03 |
MACD Line | 0.00 |
MACD Signal Line | -0.04 |
MACD Histogram | 0.0388 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.07 | ||||
Resistance 3 (R3) | 3.10 | 3.04 | 3.02 | ||
Resistance 2 (R2) | 3.04 | 2.96 | 3.02 | 3.00 | |
Resistance 1 (R1) | 2.90 | 2.91 | 2.87 | 2.87 | 2.99 |
Pivot Point | 2.84 | 2.84 | 2.82 | 2.82 | 2.84 |
Support 1 (S1) | 2.70 | 2.76 | 2.67 | 2.67 | 2.55 |
Support 2 (S2) | 2.64 | 2.71 | 2.62 | 2.54 | |
Support 3 (S3) | 2.50 | 2.64 | 2.52 | ||
Support 4 (S4) | 2.47 |